YVERDON LES BAINS, Switzerland, Dec. 20, 2016 /PRNewswire/ —Drago A. Cerchiari, Ph.D., chairman of the board of EP-Solutions SA, has announced a capital increase of 10 Million Euro to support the further development and clinical roll-out in Europeand the USA of the second generation AMYCARD system, a CE Mark-approved diagnostic device.
Dr. Werner Rainer, board member and CEO ad interim, has announced the appointment of Dr. Joaquin Azpilicueta, MD, MBA as COO of the company. Dr. Azpilicueta is a certified cardiologist with over 30 years senior executive management experience matured in Medtronic, Haemonetics and Welch Allyn.
About EP-Solutions SA:
The history of EP-Solutions SA dates back to 2009 when it was founded under the name of Amycard LLC in Moscow. In 2004, EP-Solutions SA was incorporated in Switzerland after the acquisition and transfer of assets of Amycard.
EP-Solutions SA is primarily focused on the development of innovative methods for non-invasive diagnostics and for interventional treatment of cardiac arrhythmias. The EP-Solutions system is a novel technology in ECGI class, allowing for simultaneous electrophysiology mapping on both epicardial and endocardial surfaces of the heart. The company’s unique real-time cardiac mapping technology is based over 6 years of clinical research with more than 750 patients.